The primary anticancer action of NSAIDs is assumed to be a COX-2 inhibition-mediated suppression of prostaglandin E2 production, which reduces tumor cell proliferation, angiogenesis, and enhances apoptosis. The gene discussed is PTGS2; the disease is neoplasm.